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Background: While eradicating gender disparities in cardiovascular care is a national priority, little is known about sex differences in rates of 
compliance to outpatient cardiovascular performance measures (PMs).
Methods: We evaluated whether women were as likely as men to receive established ACC/AHA PMs among the first 14,000+ outpatients enrolled 
into the ACC’s IC3 (Improving Continuous Cardiac Care) Program; the first prospective, office-based, cardiac quality improvement program in the U.S. 
Using modified Poisson regression models adjusted for site, physician, age, and race, we compared compliance rates between men and women for 7 
select coronary artery disease (CAD), heart failure (HF) and atrial fibrillation PMs during their initial enrolment visit into IC3.
Results: There were 14,414 patients enrolled from 20 practices during 7/08 to 6/09 . Of these, 7671 (53.2%) were men. For CAD, rates of PM 
compliance were similar between men and women for use of beta-blockers after MI (86.4% for men, 85.6% for women; adjusted Rate Ratio [aRR], 
0.98 [95% CI: 0.94-1.02]; p=0.37), antiplatelet therapy (84.4% vs. 83.2%; aRR, 0.98 [0.96-1.00]; p=0.08), and lipid lowering therapy (85.6% vs. 
81.5%; aRR, 0.96 [0.91-1.01]; p=0.11) but were lower in women for ACE inhibitor or ARB therapy for left ventricular systolic dysfunction (LVEF <40%) 
(72.1% vs. 71.7%; aRR, 0.96 [0.92-1.00]; p=0.05). For HF with left ventricular dysfunction, PM rates were similar between men and women for 
use of beta-blocker (92.4% vs. 91.9%; aRR, 0.99 [0.95-1.03]; p=0.64) and ACE inhibitor or ARB therapy (84.1% vs. 86.7%; aRR, 1.03 [0.97-1.10]; 
p=0.32). For atrial fibrillation, use of warfarin was lower for women in eligible patients (80.7% vs. 75.7%; aRR, 0.94 [0.89-0.99]; p=0.03).
Conclusions: Initial insights into the quality of outpatient care from the IC3 Program suggest comparable rates of compliance for men and women 
in key PMs, although small differences were observed for rates of anti-coagulation among eligible patients with atrial fibrillation and ACEI/ARB use 
in eligible CAD patients. Importantly, adherence rates among ideal patients ranged from 72%-92% suggesting an opportunity to improve care for all 
patients.
